No Data
Information on individual stocks.
Chordi<190A.T> has sharply fallen. A notification was received from Ono Pharmaceutical<4528.T>, the licensee of the 'CTX-177 (ONO-7018)', which is an inhibitor of the translocation protein associated with mucosal-related lymphoid tissue lymphoma, stating that development is to be discontinued for strategic reasons, and the rights will be returned to the company. Sea U C<9158.T> declined significantly for the fourth consecutive day, hitting a year-to-date low. The consolidated net profit for the fiscal year ending March 2025 was announced to be 3.131 billion yen (previously
Stocks that moved and those that were traded in the front market.
* Komatsu Wall <7949> 1780 - The significant increase in the dividend plan raises the appeal of the yield. * Sumitomo Pharma <4506> 787 +100 The substantial upward revision beyond expectations has an impact. * Square Enix HD <9684> 8121 +993 3D Investment emerged as a major shareholder. * S.M.S <2175> 1360 +168 The forecast of double-digit profit growth this period and the strengthening of shareholder returns are well received. * Genky Drug Stores <9267> 3630 +42
Stable, U.S. stocks are resilient and the buying intent continues.
[Emerging Markets Individual Stock Strategy] Today's emerging markets are expected to show a solid performance. The Dow Inc average rose by 114.09 dollars (+0.28%) in the US stock market two days ago on the 28th. Expectations for tax cuts and a stable bond market supported stock prices, while uncertainties regarding tariffs and the decline of NVIDIA (NVDA) weighed on them. Yesterday, on the 29th, it increased by 300.03 dollars (+0.75%) to 40,527.62 dollars, marking a sixth consecutive rise. Treasury Secretary Yellen stated that trade negotiations are progressing.
Soleosia, Morpho and others [Emerging Markets press release]
＜190A＞The development of ChordiaCTX-177 (ONO-7018) has been discontinued. ＜2937＞ Changes have been made to some contents of the Sunkus shareholder benefits. ＜3653＞ Morpho Holdings has strengthened its capital and business alliance with Mickware, which engages in the planning, development, production, and sales of computer systems. ＜4597＞ Soleidia has started patient registration for the Phase Ib/II clinical trial of SP-05. ＜9166＞ GENDA operates "TSUTAYA" in Japan.
Chordia Therapeutics Regains Rights to CTX-177 as Ono Discontinues Development
Chordia Therapeutics
＜190A＞Chordia Therapeutics Inc. Mitsubishi UFJ Capital Co., Ltd. (Partnership Name) Mitsubishi UFJ Life Sciences No. 1 Investment Limited Partnership Shareholding ratio 5.89% → 4.85% Reporting obligation date 2025/04/18